Tetra Bio-Pharma Inc. Announces Termination of Its “On The Market” Offer
OTTAWA, ON, November 4, 2021 / PRNewswire / – Tetra Bio-Pharma Inc. (“Tetra“or the”Society“) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in the discovery and development of cannabinoid-derived drugs, today announced the end of its equity offering program Previously announced “to market” (the “”ATM program“) with Canaccord Genuity Corp. as sole agent.
The termination of the ATM program takes effect from November 11, 2021. Tetra will not use the ATM program. The ATM program was created on May 28, 2021, allowing the Company to issue and sell up to $ 10 million total amount of common shares of the Company to the public from time to time at the discretion of the Company. As of the date of this announcement, Tetra had not sold any of its common shares under the ATM program.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) is a leader in the discovery and development of cannabinoid-derived drugs with an FDA and Health Canada approved clinical program to deliver new drugs and treatments by prescription to patients and their health care providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation and oncology. With patients at the heart of our business, Tetra Bio-Pharma strives to provide rigorous scientific validation and the safety data required for inclusion in the existing biopharmaceutical industry by regulators, physicians and insurance companies. .
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain statements in this press release may contain forward-looking information. All statements, other than historical facts, that deal with activities, events or developments that the Company believes, anticipates or anticipates will occur or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “have”. ‘intention to’, “plan” or “project” or the negative of those words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events differ materially from current expectations include, but are not limited to, the inability of the Company to obtain sufficient funding to execute the Company’s business plan; competition; regulations and costs and delays. anticipated and unforeseen events, the success of the Company’s research and development strategies, including the success of this or any other product, the applicability of the discoveries made therein, the successful completion and on time and uncertainties related to the regulatory process, the schedule of clinical trials, the timing and results of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record filed with the relevant securities regulatory authorities. Although the Company has attempted to identify material factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause actual results or events to differ. are not those anticipated, estimated or expected. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company does not undertake to publicly update these forward-looking statements to reflect new information, subsequent events or otherwise, unless applicable securities do not require it. legislation.
View original content to download multimedia: https://www.prnewswire.com/news-releases/tetra-bio-pharma-inc-announces-termination-of-at-the-market-offering-301417309.html
SOURCE Tetra Bio-Pharma Inc.